Trial Profile
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Early infantile epileptic encephalopathy 2
- Focus Registrational; Therapeutic Use
- Acronyms EPIK
- Sponsors Xenon Pharmaceuticals
- 30 Jun 2023 Last checked against ClinicalTrials.gov record.
- 26 Jun 2023 Status changed from recruiting to discontinued on sponsor decision; Not a safety decision.
- 26 May 2023 This trial has been completed in France (End Date: 16 May 2023), according to European Clinical Trials Database record.